Physician profile
Michael Toprover
NPI 1376980888
$11,326.66
in general payments reported to CMS, 2019-2025
5 companies · $2,267 in 2025
The $2,267 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,219 · 2022: $1,827 · 2023: $5,840 · 2024: $173 · 2025: $2,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,275 · Consulting Fee: $2,140 · Travel and Lodging: $1,230 · Food and Beverage: $531 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,275.00 |
| Consulting Fee | $2,140.00 |
| Travel and Lodging | $1,229.73 |
| Food and Beverage | $531.46 |
| Education | $104.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $7,059.46 | 2021-2023 | Krystexxa |
| Sobi, INC | $2,236.55 | 2025 | |
| Ani Pharmaceuticals, INC. | $1,700.00 | 2022 | |
| Amgen INC. | $203.42 | 2024-2025 | Krystexxa |
| Medtronic, INC. | $127.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Toprover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.